SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

Corey A Siegel,1,2 Gil Y Melmed,2 Dermot PB McGovern,2 Victoria Rai,3,4 Florian Krammer,5 David T Rubin,2,3 Maria T Abreu,6 Marla C Dubinsky,6,7 on behalf of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD)

BACKGROUND
The COVID-19 pandemic has claimed the lives of nearly 2 million people worldwide.1 Following rapid sequencing of SARS-CoV-2, pharmaceutical companies and academic institutions rapidly generated vaccine candidates on the back of a variety of both established and novel vaccine platforms.2-4 Vaccines accelerated at unprecedented pace to phase 3 development, and in December 2020, two mRNA vaccines and one inactivated vaccine were authorised for use in a number of countries. Additional vaccine platforms and candidates are in late stages of phase 3 testing.5 Prioritisation of vaccine access is generally determined by regional health authorities on the basis of risk of SARS-CoV-2 exposure and risk of developing complications from COVID-19 in order to equitably protect and promote global public well-being.6-8

IBD, including Crohn’s disease and ulcerative colitis, are characterised by chronic intestinal inflammation due to immune dysregulation. IBD is often treated with immune-modifying therapies including corticosteroids, immunomodulators, biologic agents including monoclonal antibody inhibitors of tumour necrosis factor (TNF) alpha, interleukin 12/23, integrins and small molecules such as Janus kinase (JAK) inhibitors. Prior studies have evaluated the safety and effectiveness of various vaccines in patients with IBD, with specific focus on the impact of immune-modifying therapies on serologic responses. In general, non-live vaccines are considered safe in patients with IBD regardless of IBD therapy, although those on specific types of immune-modifying treatments at the time of vaccination may have reduced vaccine immune responses.9-12 In spite of decreased efficacy associated with immune-modifying medication, most vaccines are broadly recommended for those with IBD.13-15 Patients with immune conditions (including IBD) were excluded from the SARS-CoV-2 vaccine clinical development programmes,16 and novel vaccine platforms not previously studied in IBD populations are now authorised in many countries. Therefore, many questions regarding the safety and effectiveness of SARS-CoV-2 vaccination in patients with IBD have emerged with urgent clinical relevance.

The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) is a global organisation of clinician researchers dedicated to the study and management of IBD. There are currently 60 active members and 32 senior members of IOIBD representing 27 countries. In March 2020, IOIBD rapidly developed recommendations for the clinical management of patients with IBD during the COVID-19 pandemic.17 Now that vaccinations are available, this group reconvened to develop specific recommendations pertaining to the use of SARS-CoV-2 vaccines in IBD populations.

METHODS
We used the modified Delphi method to develop consensus statements regarding SARS-CoV-2 vaccination for patients with IBD.18 The main characteristics of this technique include expert opinion with anonymous voting on statements, iteration with controlled feedback of group opinion and statistical aggregation of the group response.19

A consensus meeting was planned for 18 December 2020. The invitees for this meeting included the membership of IOIBD and additional content experts including an IBD specialist with expertise in vaccinations (GM) and a vaccinologist (FK) with expertise in vaccine development and immune responses to vaccines. Prior to this planned meeting, a questionnaire was developed by authors (CS, GM, MD, DM, MA, DR) to include statements in domains that impact clinical decisions around vaccination for the IBD population. The domains included general issues of vaccines and IBD; risk of COVID-19 to patients with IBD and need for SARS-CoV-2 vaccination; efficacy and safety of the various SARS-CoV-2 vaccines for patients with IBD; timing of when to receive SARS-CoV-2 vaccination; the influence of IBD medications on the decision and timing for SARS-CoV-2 vaccination and prioritisation of patients with IBD for SARS-CoV-2 vaccination. Forty-four statements were created and participants were asked to respond to each statement on a scale from 1 to 10 (1=do not agree at all and 10=agree completely). A priori rules determined that a statement would be accepted if at least 75% of participants scored the statement between 7 and 10. If a 75% consensus was not achieved, it would be discussed during the live meeting, followed by a second round of voting. Statements that were accepted in the first round but had a SD ≥2 or had a proportion of responses between 75% and 77% were also reviewed and voted on a second time if there was particular concern from the participants. If the second round of voting during the live meeting did not achieve consensus of 75% or higher of the respondents, then the statement was not accepted.

The questionnaire was sent electronically using Google Forms (Menlo Park, California, USA) to all voting participants on 11 December 2020. A literature review was provided to the participants prior to the meeting including evidence directly relevant for proposed statements. These included Grading of Recommendations, Assessment, Development and Evaluations...
(GRADE) evidence tables on published vaccine response trials in IBD and key articles addressing specific statements, systematic reviews and large cohorts on COVID-19 outcomes in IBD, societal and national positions on SARS-CoV-2 vaccination in pregnancy and reviews and published phase 3 data on SARS-CoV-2 vaccines including potential relevance for IBD. Results from round 1 of voting were analysed using simple descriptive statistics to include the proportion of respondents voting in the 7–10 range for each statement, mean and SD.

The live virtual meeting took place using Zoom Video Communications (San Jose, California, USA). The meeting commenced with a presentation by the vaccinologist and focused on immunity related to vaccination, various platforms being used to develop SARS-CoV-2 vaccines and efficacy and safety based on available data. All participants had an opportunity to ask questions during a discussion period. Next, results from round 1 of voting were presented and all discussions and revoting occurred based on the a priori rules described above. Three new statements were added related to pregnancy and lactation based on feedback from the participants and these went through one round of voting during the live meeting.

### Results

In the first round of voting, there were 64 respondents. This included 54 (84%) adult gastroenterologists, 4 (6%) paediatric gastroenterologists, 5 (8%) surgeons and 1 (1%) pathologist. Respondents represented North America (25), South America (2), Europe (27), Israel (4), Asia (5) and New Zealand (1). Of the 44 statements, 32 were accepted and 12 statements were not accepted in the first round of voting. For the 32 statements that were accepted the mean proportion of votes within the 7–10 range was 89.2% (mean 8.52, SD 1.57). This is in contrast to the 12 statements that were not accepted where the mean proportion of votes within the 7–10 range was 77.5% (mean 7.87, SD 1.70). 100% of the 32 statements that were accepted in the first round of voting were accepted in the second round of voting. An additional 12 statements were not accepted in the first round of voting. These 12 statements were not submitted for the second round of voting.

### Table 1

| Accepted statements | Proportion agreement | Strength of agreement (Mean) | SD |
|---------------------|----------------------|-----------------------------|----|
| **General issues of vaccines in IBD** | | | |
| Vaccinations are not associated with the onset of IBD. | 95.3% | 9.22 | 1.53 |
| Patients with IBD, irrespective of whether they are receiving immune-modifying therapies, can safely receive all non-live vaccines for vaccine-preventable illnesses. | 100% | 9.47 | 0.76 |
| Patients with IBD who are receiving immune-modifying therapies should not receive live virus vaccines while they are receiving their immune-modifying therapies. | 85.9% | 8.27 | 1.95 |
| Patients with IBD are able to mount an immune response to various vaccines, although immune-modifying therapies partially blunt that response. | 98.4% | 8.79 | 1.08 |
| Patients with IBD receiving infliximab infusions can receive non-live vaccinations on the day of their infusion or in mid-cycle without reduction in efficacy and safety. | 87.5% | 8.22 | 1.65 |
| **Risk of COVID-19 to patients with IBD and need for SARS-CoV-2 vaccination** | | | |
| Patients with IBD are at the same risk of infection with SARS-CoV-2 as compared with the general population. | 90.6% | 8.55 | 1.61 |
| Patients with IBD should be vaccinated against SARS-CoV-2. | 98.4% | 9.20 | 1.12 |
| **Timing of when to receive SARS-CoV-2 vaccination** | | | |
| The best time to administer SARS-CoV-2 vaccination in patients with IBD is at the earliest opportunity to do so. | 95.3% | 8.91 | 1.27 |
| Disease activity of IBD should not impact the timing of SARS-CoV-2 vaccination. | 90.0% | 8.50 | 1.55 |
| Vaccination against SARS-CoV-2 is unlikely to cause a flare of IBD. | 89.1% | 8.31 | 1.38 |
| SARS-CoV-2 vaccination can be administered to patients with IBD during induction with biologic therapies irrespective of timing within the treatment cycle. | 97.5% | 8.33 | 1.14 |
| SARS-CoV-2 vaccination can be administered to patients with IBD on maintenance biologic therapies irrespective of timing within the treatment cycle. | 100% | 8.93 | 1.00 |
| **The prioritisation of patients with IBD for SARS-CoV-2 vaccination** | | | |
| Healthcare/essential workers with IBD should be vaccinated in the same prioritisation tier as healthcare/essential workers without IBD. | 92.2% | 8.84 | 2.00 |
| Individuals who are not healthcare/essential workers and have no risk factors for complications of COVID-19 but have IBD should be vaccinated in the same prioritisation tier as those who are non-healthcare/essential workers and have no risk factors for SARS-CoV-2. | 82.5% | 8.02 | 2.03 |
| Individuals at increased risk for complications of COVID-19 based on age or comorbidities who also have IBD should be vaccinated in the same prioritisation tier as individuals at increased risk for complications of COVID-19 without IBD. | 96.8% | 9.13 | 1.07 |
| Individuals with IBD who are on immune-modifying therapies but are not otherwise at risk for complications of COVID-19 should be vaccinated in the same prioritisation tier as those who are ‘immunocompromised’. | 81.3% | 8.09 | 1.80 |
| Once SARS-CoV-2 vaccinations are authorised for children, guidance for vaccination of children with IBD will be the same as for children without IBD. | 100% | 8.90 | 1.03 |
| Households contacts of patients with IBD are encouraged to receive SARS-CoV-2 vaccination. | 97.4% | 9.08 | 1.34 |
| Household contacts of patients with IBD should avoid live, replication-competent SARS-CoV-2 vaccination. | 81.6% | 7.71 | 2.04 |
| Women with IBD planning pregnancy should be encouraged to receive the SARS-CoV-2 vaccine prior to attempting conception, but not delay conception solely to wait for vaccination. | 100% | 8.87 | 1.03 |
| SARS-CoV-2 vaccines should be offered to pregnant women with IBD in accordance with regional recommendations for pregnant women without IBD. | 100% | 8.97 | 1.07 |
| SARS-CoV-2 vaccines should be offered to lactating women with IBD in accordance with regional recommendations for lactating women without IBD. | 100% | 8.81 | 1.08 |
not accepted and had a mean proportion of votes within the 7–10 range of 63.5% (mean 7.01, SD 2.18).

The live virtual meeting included 40 voting participants, all of whom voted in round 1. The invited vaccinologist was a non-voting participant. Participants included 34 (88%) adult gastroenterologists, 2 (5%) paediatric gastroenterologists, 2 (5%) surgeons and 1 (1%) pathologist. Participants represented North America (18), South America (2), Europe (13), Israel (3), Asia (3) and New Zealand (1). Eighteen statements were revoted on in this meeting. Twelve of these statements had previously not been accepted, three were new statements that allowed further clarification of original statements from round 1, and one had an SD ≥2.

After round 2, there were a total of 49 statements. Forty-four of these 49 statements were accepted. A complete list of all accepted statements is reported in tables 1 and 2. Highlighted themes of the accepted statements are included in box 1.

**DISCUSSION**

The approval of SARS-CoV-2 vaccinations in many regions worldwide creates an urgency to develop recommendations for patients with IBD and other immune-mediated diseases. The IOIBD membership is an international representation of IBD specialists and created these consensus statements to help guide the highly engaged IBD community.

The panel recommends vaccinating all patients with IBD as soon as they are able to receive the vaccine, regardless of immune-modifying therapies. The exception is for any live-attenuated virus vaccines or replication-competent viral vector vaccines that come to market. There are many nuances that were addressed with the 44 accepted statements. The statements address the safety and efficacy of emerging vaccine types, the impact of different classes of IBD therapies on vaccination safety and response and priority of patients with IBD as compared with people without IBD. The overarching theme of these statements is that people with IBD should be vaccinated according to their overall risk of exposure to and risk of complications from SARS-CoV-2. These risks continue to be explored in registries such as Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE) and other population-based studies.

There was debate around the language of statements regarding pregnancy. Due to discrepant guidance from different regions of the world, a decision was made to add the phrase ‘in accordance with regional

---

**Table 2 Accepted statements related to SARS-CoV-2 vaccination for patients with IBD by the IOIBD**

| Accepted statements | Proportion agreement | Strength of agreement (Mean) SD |
|---------------------|----------------------|---------------------------------|
| **Efficacy and safety of the various SARS-CoV-2 vaccines for patients with IBD** | | |
| SARS-CoV-2 vaccination will be effective in patients with IBD to prevent COVID-19. | 82.8% | 8.13 | 1.46 |
| Patients with IBD who should receive the same vaccine dosing regimen as patients without IBD. | 85.9% | 8.44 | 1.62 |
| Patients with IBD receiving SARS-CoV-2 vaccination should be referred to registries tracking vaccination effects. | 95.3% | 9.05 | 1.25 |
| Messenger RNA vaccines are safe to administer to patients with IBD. | 82.5% | 7.92 | 1.74 |
| Replication-competent vector vaccines are safe to administer to patients with IBD. | 95.2% | 8.81 | 1.02 |
| Inactivated SARS-CoV-2 vaccines are safe to administer to patients with IBD. | 89.1% | 8.16 | 1.78 |
| Recombinant SARS-CoV-2 vaccines are safe to administer to patients with IBD. | 90.2% | 8.18 | 1.61 |
| SARS-CoV-2 vaccines that contain whole or fragments of coronavirus proteins combined with an adjuvant to enhance immune response are safe to administer to patients with IBD. | 76.6% | 7.55 | 1.89 |
| Live attenuated vaccines for SARS-CoV-2 are not considered safe for patients with IBD who are receiving immune-modifying therapies or expected to receive immune-modifying therapies within the next 8 weeks. | 84.1% | 8.37 | 1.71 |
| IBD specialists should trust national and international regulatory bodies for appropriate review and authorisation of SARS-CoV-2 vaccinations. | 95.3% | 8.69 | 1.22 |
| **The influence of IBD medications on the decision and timing for SARS-CoV-2 vaccination** | | |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving oral or topical 5-ASA medications. | 96.9% | 9.41 | 1.00 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving systemic corticosteroids. | 87.5% | 8.20 | 1.65 |
| Patients with IBD vaccinated with SARS-CoV-2 vaccine should be counselled that vaccine efficacy may be decreased when receiving systemic corticosteroids. | 92.5% | 8.53 | 1.99 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving thiosphurine or methotrexate monotherapy. | 88.9% | 8.32 | 1.83 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving monotherapy with an anti-TNF agent. | 95.3% | 8.86 | 1.31 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving monotherapy with an anti-IL12/23 or anti-IL23 agent. | 90.3% | 8.69 | 1.53 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving monoclonal therapy with an anti-integrin agent. | 93.8% | 9.08 | 1.34 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving a biologic in combination with a thiosphurine or methotrexate. | 82.8% | 8.11 | 2.05 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving therapy with an IL-23 inhibitor. | 76.2% | 7.83 | 2.21 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving therapy with an S1P receptor agonist. | 75.0% | 7.72 | 1.89 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is in a clinical trial for an IBD medication, as permitted per protocol. | 87.5% | 8.53 | 1.52 |

ASA, aminosalicylic acid; JAK, janus kinase; S1P, sphingosine-1-phosphate; TNF, tumour necrosis factor.
Box 1 Highlighted themes of accepted statements related to SARS-CoV-2 vaccination for patients with IBD by the International Organization for the Study of Inflammatory Bowel Disease (IOIBD)

- Patients with IBD should be vaccinated against SARS-CoV-2.
- The best time to administer SARS-CoV-2 vaccination in patients with IBD is at the earliest opportunity to do so.
- SARS-CoV-2 vaccines including messenger RNA vaccines, replication-incompetent vector vaccines, inactivated vaccines and recombinant vaccines are safe to administer to patients with IBD.
- SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving immune-modifying therapies.
- Patients with IBD vaccinated with SARS-CoV-2 should be counselled that vaccine efficacy may be decreased when receiving systemic corticosteroids.

recommendations. Our statements convey that if SARS-CoV-2 vaccinations are considered safe for pregnant women without IBD, then they should be considered safe for pregnant women with IBD.

A significant proportion of the live virtual meeting focused on the expected immune response to a SARS-CoV-2 vaccine while a patient is receiving immune-modifying medications. The participants endorsed the statement that people with IBD are able to mount an immune response to various vaccines, although immune-modifying therapies may partially blunt that response. This was felt not to be a reason to delay vaccination or stop immune-modifying therapies, but rather a reason to recommend counselling patients receiving systemic corticosteroids that efficacy may be decreased.

Several questions emerge in vaccinating patients with IBD against COVID-19. Will the vaccines’ effectiveness be affected by IBD medications? Will the vaccines be safe on a background of immunosuppression? Efficacy of the vaccines has been measured as cases of COVID-19 following immunisation (generally a week or two after the booster dose). Immune responses (IgG) and T cell responses (mRNA, AdV) against the spike protein. It is not currently known what the threshold titres are to achieve protection. While most current vaccines currently in development,© because of the size of these IBD cohorts, the actual efficacy of vaccines to prevent disease even in patients who did not achieve threshold titres is not known.

The current vaccines in phase 2/3 studies for SARS-CoV-2 have achieved high levels of antibody responses (IgG) and T cell responses (mRNA, AdV) against the spike protein. The panel recognises that both the development of the statements as well as the consensus responses were limited by the lack of available data and based on expert opinion, including guidance from a vaccinologist. Despite data gaps, the global IBD patient and professional communities need guidance in the face of such uncertainty. These consensus statements are meant to inform clinical decision-making but should not replace individualised management decisions. Real-world data from registries will help generate data on vaccine outcomes in patients with IBD to inform future recommendations.

Correction notice This article has been corrected since it published Online First. The provenance and peer review statement has been included.

Acknowledgements The authors would like to thank Professor Florian Krammer for his time spent on the live webinar to educate and answer questions from the IOIBD participants, and Marischa Konings for her organisation of the programme. Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Voting members of the consensus panel Maria T Abreu; Vinnet Ahuja; Matthieu Allez; Ashwin N Ananthakrishnan; Charles N Bernstein; Jonathan Braun; Yehuda Chowers; Jean-Frédéric Colombel; Silvio Danese; Axel Dignass; Iris Dotan; Marla Dwinski; Phillip R Flesner; Christoph Gasche; Richard B Gearry; Subrata Ghosh; Anne M Griffiths; Stephen B Hanauer; Ailsa L Hart; Gilaad G Kaplan; Arthur Kaser; Paulo Subrata Ghosh; Anne M Griffiths; Stephen B Hanauer; Ailsa L Hart; Gilaad G Kaplan; Arthur Kaser; Paulo G Kotze; Ioannis E Koutroubakis; Wolfgang Kuoß; Peter L Lakatos; Ari Leiverman; James D Lewis; James O Lindsay; Edward V Loftus Jr.; Edoardo Louis; Milan Lukas; Fernando Magro; Uma Mahadevan; Gerasimos J Mantzaris; Dmitri PB McGovern; Gil Y Melmed; Björn
To cite Siegel CA, Melmed GY, McGovern DB, et al. Gut 2021;70:635–640.
Received 29 December 2020
Accepted 30 December 2020
Published Online First 20 January 2021
Gut 2021;70:635–640.
doi:10.1136/gutjnl-2020-324000

ORCID iDs
Corey A Siegel http://orcid.org/0000-0002-2240-6605
David T Rubin http://orcid.org/0000-0001-5647-1723
María C Dubinsky http://orcid.org/0000-0003-4968-5795

REFERENCES
1. Available: https://coronavirus.jh.edu/map.html [Accessed on December 20, 2020].
2. Wrapp D, Wang N, Corbett KS, et al. Cryo-Em structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367:1260–3.
3. Wrapp D, De Vlieger D, Corbett KS, et al. Structural basis for potent neutralization of Betacoronaviruses by single-domain camelid antibodies. Cell 2020;181:1004–15.
4. Corbett KS, Ellis DK, Liert SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 2020;586:56–71.
5. Krammer F. SARS-CoV-2 vaccines in development. Nature 2020;586:516–27.
6. Persad G, Peek ME, Emanuel EJ. Fairly prioritizing groups for access to COVID-19 vaccines. AMA J 2020. doi:10.1001/jama.2020.18513. [Epub ahead of print: 10 Sep 2020].
7. Available: https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html [Accessed on May 9, 2020].
8. Available: https://apps.who.int/iris/bitstream/handle/10665/33240/WHO-2019-nCoV-SAGE_Framework-Allocation_and_prioritization-2020.1-eng.pdf [Accessed December 20, 2020].
9. Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccine in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:148–54.
10. deBruijn AC, Hilden R, Forsea K, et al. Immuneogenicity and safety of influenza vaccine in children with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:25–33.
11. Andriani S, Frasca D, Romero M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti-TNF-α agents: effects of combined therapy with immunosuppressants. J Crohns Colitis 2013;7:301–7.
12. Foino G, Peryrin-Brioulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2012;18:1042–7.
13. Farfay FA, Melmed GY, Lichtenstein GR, et al. Acg clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol 2017;112:241–58.
14. Manser CN, Maillard MH, Rogler G, et al. Vaccination in patients with inflammatory bowel diseases. Digestion 2010;81:138–2603–15.
15. Lopez A, Mariette X, Bachelez H, et al. Vaccination recommendations for the adult immunosuppressed patient: a systematic review and comprehensive field synopsis. J Autoimmun 2017;80:10–27.
16. Polack FF, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2689–700.
17. Rubin DT, Abreu MT, Rai V, et al. International Organization for the Study of Inflammatory Bowel D Management of Patients with Crohn’s Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an International Meeting. Gastroenterology 2020.
18. Fitch K, Bernstein SJ, Aguilar MD, et al. The RAND/ UCLA Appropriateness Method User’s Manual. Santa Monica, California: RAND, 2001.
19. Murphy MK, Blau NA, Langer B, et al. Consensus development methods, and their use in clinical Guideline development. Health Technol Assess 1998;2:1–88.
20. Bentheim EL, Tse F, Carroll M, et al. 124 Canadian association of gastroenterology clinical practice guidelines on immunizations in inflammatory bowel disease. Gastroenterology 2020;158:29–32.
21. deBruijn J, Forsee K, et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm Bowel Dis 2016;22:638–47.
22. Rahier J, Papay P, Salleron J, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011;60:456–62.
23. Pinetón de Chambrun G, Dauchet L, Gouyer R, Sze G, et al. Vaccination and risk for developing inflammatory bowel disease: a meta-analysis of case-control and cohort studies. Clin Gastroenterol Hepatol 2015;13:1405–15. [Epub ahead of print: 24 Mar 2015].
24. Unger RC, Brenner EI, Geary RB. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021;70:725–32.
25. Singh AK, Jena A, Kumar M-P, et al. Risk and outcomes of coronavirus disease (COVID-19) in patients with inflammatory bowel disease: a systematic review and meta-analysis. European Gastroenterol J 2021;20560662097260.
26. D’Amico F, Danese S, Peyrin-Biroulet L. Systematic review on inflammatory bowel disease patients with coronavirus disease 2019: it is time to take stock. Clin Gastroenterol Hepatol 2020:0.
27. Available: https://www.rcoz.org.uk/news/covid-19-vaccination-and-pregnancy/ [Accessed December 20, 2020].
28. Available: https://www.acog.org/c clinical-guidance/practice-advisory/articles/2020/12/ vaccinating-pregnant-and-lactating-patients-against-covid-19 [Accessed December 20, 2020].
29. Available: https://www.govuk/ government/publications/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcv-2-december-2020/ priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcv-2-december-2020 [Accessed December 16, 2020].
30. Available: https://www.cdc.gov/coronavirus/2019ncov/vaccines/recommendations/pregnancy.html [Accessed December 16, 2020].
31. Jeyanathan M, Akhshi S, Small F, et al. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol 2020;20:615–32.
32. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99–111.
33. Melmed GY, Rubin DT, McGovern DB, Winter is coming! clinical, immunologic, and practical considerations for vaccinating patients with inflammatory bowel disease during the coronavirus Disease-2019 pandemic. Gastroenterology 2020. doi:10.1053/j.gastro.2020.10.013. [Epub ahead of print: 14 Oct 2020].
34. Available: https://investors.moderna.com/news-releases/news-release-details/moderna-announces-primary-efiicacy-analysis-phase-3-cove-study [Accessed on December 29, 2020].
35. Pratt PK, David N, Weber HC, et al. Antibody response to hepatitis B virus vaccine is impaired in patients with inflammatory bowel disease on infliximab therapy. Inflamm Bowel Dis 2018;24:380–6.
36. Agarwal N, Ollington K, Kaneshiro M, et al. Are immunosuppressive medications associated with...
decreased responses to routine immunizations? A systematic review. *Vaccine* 2012;30:1413–24.

37 Caldera E, Hillman L, Saha S, et al. Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: a randomized clinical trial. *Inflamm Bowel Dis* 2020;26:593–602.

38 Winthrop KL, Silverfield J, Raeuwicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. *Ann Rheum Dis* 2016;75:687–95.

39 Doonekamp L, Goetgebuer RL, Schmitz KS, et al. High Immunogenicity to Influenza Vaccination in Crohn’s Disease Patients Treated with Ustekinumab. *Vaccines* 2020;8.

40 Brodmerkel C, Wadman E, Langley RG, et al. Immune response to pneumococcal and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. *J Drugs Dermatol* 2012;12:1122–9.

41 Haykir Solay A, Eser F. High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study. *Hum Vaccin Immunother* 2019;15:1177–82.

42 Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. *Gut* 2015;64:77–83.

43 Petsch B, Schnee M, Vogel AB, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. *Nat Biotechnol* 2012;30:1210–6.

44 Saroib A, Perlman S. Lessons for COVID-19 immunity from other coronavirus infections. *Immunity* 2020;53:248–63.

45 Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. *J Virol* 2010;84:9318–25.

46 Ni L, Ye F, Cheng M-L, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. *Immunity* 2020;52:971–7.